emugrobart

all catalysts(0)

nothing on the calendar yet

News(4)

• Roche cans muscle-preserving obesity drug, hands it back to Chugai
  Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with an anti-obesity injectable. The Swiss pharma is stopping work on emugr…
  endpoints · 12h ago
• Roche drops muscle-sparing obesity antibody after flunked interim analysis
  Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.
  fiercebiotech · 15h ago
• Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
  Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…
  biospace · 1mo ago
• Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
  Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.
  fiercebiotech · 1mo ago